Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. - Wikidata - wikimedia - TriplyDB

Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.

Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.

http://www.wikidata.org/entity/Q35183631

about

Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics.Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey.Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy.Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys.Transport of anti-IL-6 antigen binding fragments into cartilage and the effects of injury.Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis.Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013 Sirukumab: A Potential Treatment for Mood Disorders?Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6.Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis Aberrant B-lymphocyte responses in lupus: inherent or induced and potential therapeutic targets.Tocilizumab in pediatric rheumatology: the clinical experience.Monoclonal antibody treatments for rheumatoid arthritis.Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs.Sirukumab : a novel therapy for lupus nephritis?New treatments for inflammatory rheumatic disease.Novel investigational drugs targeting IL-6 signaling for the treatment of depression.Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.IL-6 blockers in systemic onset juvenile idiopathic arthritis.The safety of pharmacological treatment options for lupus nephritis.Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials.Advances in the treatment of cutaneous lupus erythematosus.Sirukumab: a promising therapy for rheumatoid arthritis.An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo.Functions of interleukin-34 and its emerging association with rheumatoid arthritis.Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.Ethnic sensitivity assessment - pharmacokinetic comparability between Japanese and non-Japanese healthy subjects on selected mAbs.Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach.Absolute Bioavailability and Pharmacokinetic Comparability of Sirukumab Following Subcutaneous Administration by a Prefilled Syringe or an Autoinjector.Investigational drugs in systemic vasculitis.Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study.Deciphering the In Vivo Performance of a Monoclonal Antibody to Neutralize Its Soluble Target at the Site of Action in a Mouse Collagen-Induced Arthritis Model.Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients.

P2860

Q26769917-3561CC8E-6B01-4C93-BEEF-2A3503320521 Q26823465-88958FE7-2297-422D-BBA3-E5909B6EFB34 Q28076558-BBD11D44-E983-409C-948C-B04567559A51 Q28088753-068E1714-2E7F-45AE-BE7E-AF42AC335CD7 Q30566003-710B1CF1-FA89-4CBE-BB0B-A1A2489D63B0 Q31091923-32C4F761-7198-410D-BD26-7A909CE062E3 Q35582297-D26FDCFD-DC75-4369-BAE3-CAC977E03A1F Q36579912-89E1BD38-FFEB-4D4A-B7E6-B25D509008A1 Q36681123-5DB5DB2D-DC85-4861-8B85-05458398AC09 Q37331009-73C3289C-85BF-4F55-B5FC-F64C6D2563E2 Q37456300-0685EBB4-2C0D-4D6C-8A15-55664DAA6208 Q37496388-C5A46376-91EA-411E-87E4-1EE15593D238 Q37562443-5B124A87-50CC-4E28-BA0D-A655D39EE4C1 Q37600383-DEA4531E-A6ED-41C9-83C7-D669D5C9CFE4 Q38091288-AB0D921E-4B29-47EC-A992-180E7CB502D8 Q38108851-8905AAB2-50A8-4AA6-9397-F79AAECD2D5C Q38110210-89BF8649-6E3B-4880-BC34-26A0732DF20A Q38116065-9CEAB522-13A2-49F9-A124-631BB410681C Q38207142-93528459-3E21-47E6-B871-0956FAF48C93 Q38246130-AB4A02ED-8568-4789-8DDD-BF8E26831B48 Q38266252-5F94D4F0-2BD7-4F96-96DF-93E1DCB26899 Q38317241-18A8485C-5236-43F9-891A-041252DF0D43 Q38371450-89CB5EAA-DDD2-476D-9DE9-CAE48F879BDE Q38661146-0424C957-235B-494D-8CB7-D309CD096271 Q38829637-176E0FDC-D302-47FB-A417-5DF477B3E4BE Q38840646-AEA4315D-7A9A-4A9A-8BDB-B1F3CCDA2EF6 Q38851093-2341CD78-A36A-44EF-ABCE-76F110A3C2A0 Q38856800-21F22EFE-2696-496E-BA09-4FF2F408F440 Q38931171-E114A398-DB67-4585-B6BA-256D6881735E Q38934355-FFB83C83-16EC-4677-B275-2EEDEBD7843D Q39218839-39EEC883-2F79-4390-9420-9741DDC50615 Q41676322-21857586-1547-4D0F-A179-4748498774CC Q46523280-F187717C-EF9E-49CD-AC6A-F35B19542A1A Q47109861-9FA06A19-24C8-455F-B172-74E71FCB9B44 Q47692758-BBBF92A1-F962-43D2-A84A-3D5CF921B31C Q50973039-B1444118-0512-403D-A5EE-F0D54F483D93 Q51834131-6BA635CC-5F00-4890-B2DA-3E223E444B37 Q52874195-48C503E5-6276-43BE-8E42-AFBECD7DA52F Q53224491-BFFA2E69-D5A5-47D5-88D7-05B3EBA1745C Q55417294-28FF7E4E-681F-433C-AF05-12926DAA05A0

P2860

Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.

http://www.wikidata.org/entity/Q35183631

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Pharmacokinetics, pharmacodyna ...... cts in a first-in-human study.

@ast

Pharmacokinetics, pharmacodyna ...... cts in a first-in-human study.

@en

type

label

Pharmacokinetics, pharmacodyna ...... cts in a first-in-human study.

@ast

Pharmacokinetics, pharmacodyna ...... cts in a first-in-human study.

@en

prefLabel

Pharmacokinetics, pharmacodyna ...... cts in a first-in-human study.

@ast

Pharmacokinetics, pharmacodyna ...... cts in a first-in-human study.

@en

P1433

Q35183631-0D52B001-A9B7-4061-87C7-747C5A263A2E

P1476

Q35183631-C995B49D-0810-4AED-B1E2-253C93B04B19

P2093

Q35183631-20A86303-917A-412A-9987-950099989D7F

Q35183631-35F3D218-94F6-43B7-BC29-70BE7968981C

Q35183631-5CCBCB6D-4A5D-4FA0-8D61-FE006427CEFB

Q35183631-884AE980-EE3B-4539-8BD2-25D28C8EF4E0

Q35183631-BE8A3C83-C1EF-474F-9126-7880EFE26E4B

Q35183631-D40A34DD-77B3-40C1-9CD0-8A6E152691BD

Q35183631-DC561DC9-C426-4CA7-96F9-0535E5430922

Q35183631-FE3DD574-83BD-457A-A5AF-CCE618A0BF2B

P2860

Q35183631-0216510F-AD87-4C12-AEFC-A5D97A014C07

Q35183631-068DE6BC-E4DD-4A9A-8F84-7D6E85FE30F9

Q35183631-108BC541-164C-4548-BAF8-F6E003214724

Q35183631-2C10E402-0DAC-4B72-A307-4ABB0C4BB571

Q35183631-2D92D9EC-99B4-4E57-A138-60970F6768F8

Q35183631-30BCCEFC-160F-430E-AB66-238086BB98E1

Q35183631-3DD71546-0124-4C57-B434-62CB55769ABE

Q35183631-40B5EBEC-0D96-4524-BD03-474E12EA281A

Q35183631-51C2CA0C-B7F6-494B-9DC3-82E673316F49

Q35183631-5AC22F05-C7E5-4A5D-BDEF-09D53A0025CE

P304

Q35183631-4646BB1F-F35E-47FB-924D-BB324FD2C9DE

P31

Q35183631-EDCB8162-7511-4589-8355-173B9AC0266C

P356

Q35183631-46BD8A1B-0E38-471E-AFF2-457ABEED9E1A

P407

Q35183631-8AA91181-DE6E-474E-A722-A2A671F655EC

P433

Q35183631-BEEBEA97-31D1-4998-9E99-2FC0D2C1294E

P478

Q35183631-18859D18-7DA8-4FFC-B8BE-4314534DE18D

P577

Q35183631-C15D094B-776E-412A-8DA7-5F5813C808E6

P5875

Q35183631-662E591C-CC8B-4D02-ACB0-D773E594DF6E

P698

Q35183631-002A8A4A-E485-42D4-9662-4180D9407B9C

P921

Q35183631-9F7965AC-AD2F-4A81-AC40-E59CA4EDBAA3

P932

Q35183631-287AF301-59BD-418A-93EB-AA9C13760ED7

P356

J.1365-2125.2011.03964.X

P1433

British Journal of Clinical Pharmacology

P1476

Pharmacokinetics, pharmacodyna ...... cts in a first-in-human study.

@en

P2093

Bart Frederick

http://www.w3.org/2001/XMLSchema#string

Bart Van Hartingsveldt

http://www.w3.org/2001/XMLSchema#string

Craig Comisar

http://www.w3.org/2001/XMLSchema#string

Esther Bouman-Thio

http://www.w3.org/2001/XMLSchema#string

Honghui Zhou

http://www.w3.org/2001/XMLSchema#string

Hugh M Davis

http://www.w3.org/2001/XMLSchema#string

Joseph C Marini

http://www.w3.org/2001/XMLSchema#string

Zhenhua Xu

http://www.w3.org/2001/XMLSchema#string

P2860

Elimination mechanisms of therapeutic monoclonal antibodies

Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women.

Gender and age differences in systemic lupus erythematosus. A study of 489 Greek patients with a review of the literature.

Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms.

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study.

Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity.

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.

The role of C-reactive protein as a prognostic indicator in advanced cancer.

Adipocytokines and insulin resistance.

Interleukin-6: from basic science to medicine--40 years in immunology.

P304

270-281

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2125.2011.03964.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50362475

http://www.w3.org/2001/XMLSchema#string

P698

21392075

http://www.w3.org/2001/XMLSchema#string

P921

P932

3162657

http://www.w3.org/2001/XMLSchema#string